Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie

Executive Summary

GSK, Bayer, Celgene, Amgen, AstraZeneca, Bristol-Myers Squibb, Sanofi, Merck & Co and AbbVie are among the pharma companies due to report second-quarter results imminently. As the financial reporting season moves into a second week, Scrip takes a look at the key things to watch for.

Advertisement

Related Content

Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market
Jounce Gets $261m To Start, Milestone Fees Up To $2.3bn In Celgene Deal
2Q Pharma Results Preview: What Lies Ahead
Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?
Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar
GSK's Vaccines Chief Slaoui To Follow Witty Out The Door
What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
Timeline At The Top: What Witty Did At GSK
Bayer Chief Dekkers Departs With Words Of Warning, Wisdom For Pharma
Celgene Diversifying Beyond Myeloma Backbone Revlimid

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC096918

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel